Last reviewed · How we verify
Transdermal Hydrocolloid Placebo Patch
This is a placebo patch with no active pharmaceutical ingredient, designed to deliver inert hydrocolloid material transdermally for research or control purposes.
This is a placebo patch with no active pharmaceutical ingredient, designed to deliver inert hydrocolloid material transdermally for research or control purposes. Used for Clinical trial control/placebo comparator (not a therapeutic indication).
At a glance
| Generic name | Transdermal Hydrocolloid Placebo Patch |
|---|---|
| Also known as | DuoDerm, ConvaTec |
| Sponsor | University of Wisconsin, Madison |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
A transdermal hydrocolloid placebo patch is a non-medicated delivery system used in clinical trials as a control comparator. It mimics the physical characteristics and application method of an active transdermal patch but contains no therapeutic agent, allowing researchers to isolate the pharmacological effects of an investigational drug from placebo effects.
Approved indications
- Clinical trial control/placebo comparator (not a therapeutic indication)
Common side effects
- Skin irritation at application site
- Adhesion-related dermatitis
Key clinical trials
- Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children (PHASE3)
- The OBstetric Lidocaine Patch (OBLido) Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |